| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
TORONTO, Ontario & CAMBRIDGE, Mass.—ProMIS Neurosciences Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, recently announced the identification of a novel therapeutic epitope target on misfolded forms of TDP43, implicated in the development and progression of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company filed a provisional patent application for this target with the United States Patent Office on May 30, 2017.
 
Commenting on the announcement, Dr. Neil Cashman, chief scientific officer of ProMIS, stated: “Using our proprietary discovery engine, scientists at UBC and ProMIS identified both the sequence and conformational shape of this novel epitope target on misfolded TDP43 that plays a key role in ALS and frontotemporal dementia.”
 
TDP43 is present in every cell, and plays a critical role in the response of cells to oxidative stress. However, in ALS, FTD and other neurodegenerative diseases, TDP43 can lose its normal function, forming intracellular aggregates of misfolded TDP43 that disrupt cellular energy generation and normal protein degradation.
 
“Our goal is to selectively target misfolded TDP43 without disrupting the critical role that normally folded TDP43 plays in cell biology,” stated Dr. Elliot Goldstein, ProMIS president and CEO. “We plan to create and validate monoclonal antibodies against misfolded TDP43 to select optimal therapeutic candidates for advancement into the clinic.”

Related Topics

Published In

Volume 13 - Issue 8 | August 2017

August 2017

August 2017 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Red tumor cells are shown against a teal backdrop showing attachment to tissue.

Decoding the tumor microenvironment with immune profiling

Integrating multiplexed immunohistochemistry with spatial analysis offers a practical way to uncover tumor-immune dynamics.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue